CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS
An object of the present invention is to provide a cancer vaccine with use of a common cancer antigen cocktail, a TCR/CAR-T cell therapeutic, a companion diagnostic method, and a method for diagnosing risk of cancer onset by detecting circulating tumor cells. The present invention provides a cancer vaccine comprising: (1) common cancer antigens comprising three or more selected from GPC3, ROBO1, EPHB4, CLDN1, and LAT1; (2) partial peptides of the three or more common cancer antigens with CTL inducibility; (3) a dendritic cell stimulated with the partial peptides; or (4) mRNAs encoding the common cancer antigens or the partial peptides.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
One embodiment of the present invention provides a method for producing a composition for a dosimeter, the method comprising a mixing step for mixing at least a portion of a plurality of raw materials for forming a composition for a dosimeter while supplying fine bubbles of an inert gas.
The present invention provides a novel means usable for predicting a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, said means being characterized by use of blood CD8-positive effector memory T cells as a biomarker. Specifically, in order to predict a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, (i) the level of CD8-positive effector memory T cells that are contained in a blood sample which is collected from the pancreatic cancer patient is measured and (ii) when the level of the CD8-positive effector memory T cells is high, it is determined that the therapeutic effect yielded by the combination therapy is high.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
Provided is a control device for controlling movement of an endoscope. The endoscope acquires an image including a target of interest. The control device includes at least one processor. The processor is configured to acquire a position of the target of interest in a field of view of the endoscope, calculate a position of a dirt on the endoscope in the field of view, set a target region at a position different from the position of the dirt, and cause the endoscope to track the target of interest such that the target of interest is positioned within the target region based on the position of the target region and the position of the target of interest.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
5.
ENDOSCOPE SYSTEM, CONTROL DEVICE, CONTROL METHOD, AND STORAGE MEDIUM
An endoscope system includes: a processor; an endoscope; a holder configured to hold the endoscope and adjust a position and an orientation of the endoscope; and a display. The processor acquires a first position of a first port for inserting, into an examination subject, a first treatment tool, a second position of a second port for inserting, into the examination subject, a second treatment tool, and a third position of a focus target in the examination subject, and rotates the image on a basis of the acquired first, second, and third positions such that a particular relative angle is formed between a direction of a second vector, which is a projection of a first vector indicating an up-down direction of the focus target as viewed from an operator onto a plane orthogonal to a visual axis of the endoscope and an up-down direction of the image displayed on the display.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
6.
INFORMATION PROCESSING DEVICE, CONTROL METHOD, AND INFORMATION PROCESSING PROGRAM
An information processing device J includes a light control unit 32, a still image data acquisition unit P2, and an extraction unit 33. The light control unit 32 adjusts the amount of light emitted by a light emitting unit 61 and directed to an eye of a subject. The still image data acquisition unit P2 acquires a plurality of items of still image data on the basis of captured images obtained by capturing the fundus of the subject that has received the light emitted from the light emitting unit 61. The extraction unit 33 extracts extracted image data in which the fundus appears for each of the plurality of items of still image data.
The present invention ensures a surgical field on a side deeper than a tubular body inserted into a natural orifice. A disclosed surgery assistance instrument may be one that comprises a passage for a surgical instrument provided therein and is mounted on a tubular body to be inserted into a natural orifice of a living body. The disclosed surgery assistance instrument comprises: a biological tissue exclusion device that is operated so as to move biological tissue, that is on a side deeper than the leading end of the tubular body, outwardly in the radial direction of the tubular body; and a fixing mechanism for fixing the biological tissue exclusion device to the tubular body.
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
Ring Q represents an optionally substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally substituted 5- to 10-membered aromatic heterocycle, Z represents —O—, —N(R7a)—, an optionally substituted 6- to 10-membered divalent aromatic ring group, an optionally substituted 5- to 10-membered divalent aromatic heterocyclic group, an optionally substituted 4- to 10-membered divalent non-aryl heterocyclic group, and R1, R2a, R2b, R3, R4, and R5 are as described in the specification, or a pharmaceutically acceptable salt thereof.
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
9.
METHOD FOR PREDICTING PROGNOSIS OF PATIENT WITH SKELETAL MUSCLE ATROPHY OR EFFECTIVENESS OF NUTRITION THERAPY FOR PATIENT WITH SKELETAL MUSCLE ATROPHY
The present invention addresses the problem of providing a prediction method and the like capable of providing information useful for determining the prognosis of a patient with skeletal muscle atrophy or the effectiveness of nutrition therapy for the patient with skeletal muscle atrophy. The present embodiment involves predicting the prognosis of a patient with skeletal muscle atrophy or the effectiveness of nutrition therapy for the patient with skeletal muscle atrophy by using an analysis value of the phosphorylation state of a branched-chain α-keto acid dehydrogenase (BCKDH) in the liver tissue of the patient with skeletal muscle atrophy, or a concentration value of carnitines in the blood, urine, sweat, liver tissue, or muscle tissue of the patient with skeletal muscle atrophy.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
10.
TERTIARY AMIDE DERIVATIVES SUBSTITUTED WITH 4-MEMBERED RING STRUCTURE
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
[Problem] The present disclosure provides tertiary amide derivatives substituted with a 4-membered ring structure that are useful as medicines and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and therapeutic agents and/or prophylactic agents for conditions in which CBP/P300 is involved, comprising the composition.
[Solving Means] More specifically, the present disclosure provides a compound represented by the following Formula (1):
wherein A represents CHF, or CH2, B represents the following Formula (B-1):
Ring Q represents an optionally substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally substituted 5- to 10-membered aromatic heterocycle, Z represents —O—, —N(R7a)—, an optionally substituted 6- to 10-membered divalent aromatic ring group, an optionally substituted 5- to 10-membered divalent aromatic heterocyclic group, an optionally substituted 4- to 10-membered divalent non-aryl heterocyclic group, and R1, R2a, R2b, R3, R4, and R5 are as described in the specification, or a pharmaceutically acceptable salt thereof.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
22, B represents formula (B-1), the ring Q represents a six- to ten-membered aromatic hydrocarbon ring which may be substituted or a five- to ten-membered aromatic heterocyclic ring which may be substituted, Z represents –O-, -N(R7a)-, a six- to ten-membered divalent aromatic ring group which may be substituted, a five- to ten-membered divalent aromatic heterocyclic group which may be substituted, or a four- to ten-membered divalent non-aryl heterocyclic group which may be substituted, and R1, R2a, R2b, R3, R4, and R5 are as described in the specification] or a pharmaceutically acceptable salt thereof.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A medical instrument according to the present invention comprises: a structure configured to be capable of being inserted into a luminal organ having a smooth muscle; and a stimulus generation unit configured to be capable of applying a stimulus produced using at least one of heat, vibration, light, and electricity to the luminal organ in a state in which the structure is inserted into the luminal organ.
Provided is a medical stapler that is disposed on the distal end of an endoscope, the medical stapler comprising: a wire extending in the axial direction of the endoscope; and a staple discharge part having a cartridge capable of storing staples, and an ejection mechanism connected to the distal end of the wire and being capable of ejecting the staples from the cartridge. The cartridge is detachably attached to the staple discharge part. Through forward and backward movement of the wire, the ejection mechanism is movable between a first position as an initial position and a second position where the staples are ejected. The ejection mechanism is in the second position when the cartridge is detached from the staple discharge part. The ejection mechanism is moved from the second position to the first position when the cartridge is attached to the staple discharge part.
A medical stapler provided at a distal end of an endoscope includes a wire extending in an axial direction of the endoscope and a staple release part having a cartridge configured to accommodate a staple and an injection mechanism connected to a distal end of the wire and configured to eject the staple from the cartridge. The cartridge is provided so that the cartridge is removably attached to the staple release part. The injection mechanism is movable from a first position that is an initial position to a second position where the staple is ejected by manipulating the wire. The injection mechanism is located at the second position when the cartridge is removed from the staple release part. The injection mechanism moves from the second position to the first position when the cartridge is attached to the staple release part.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
16.
SURVIVOR T CELLS, SURVIVOR T CELL POPULATION, AND PHARMACEUTICAL COMPOSITION
The present disclosure provides cells that are competitive with respect to cancer cells, without experiencing starvation or exhaustion, even in glucose-depleted environments. Specifically, the present disclosure provides survivor T cells with enhanced glucose uptake capacity. The T cells are modified so as to express a glucose transporter and/or configured such that the expression of a glucose transporter is enhanced. Also provided are a cell population including such cells, a pharmaceutical composition, and a treatment method.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
The present disclosure provides cells that are competitive to cancer cells without starvation and exhaustion even in an environment in which glucose is depleted. More specifically, the present disclosure provides T cells with enhanced glucose uptake ability, wherein the T cells are modified such that the expression of glucose transporters in the T cells is regulated in response to changes in tumor microenvironmental conditions, and/or the T cells comprise a nucleic acid sequence encoding a glucose transporter operably linked to a tumor microenvironment sensing element that senses changes in tumor microenvironmental conditions.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
An image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry acquires a first image including a first region image in which a common subject is imaged and a second image including a second region image corresponding to the first region image, on the basis of a first pixel value constituting the first region image and a first reference value, estimates the confidence level of the first pixel value, on the basis of a second pixel value constituting the second region image and a second reference value different from the first reference value, estimates the confidence level of the second pixel value and acquires the confidence level of a subtraction value between the first pixel value and the second pixel value on the basis of the confidence level of the first pixel value and the confidence level of the second pixel value.
G06T 5/20 - Amélioration ou restauration d'image utilisant des opérateurs locaux
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
19.
KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCER
An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
20.
Method of Quantifying Antigen-Binding Molecule Bound to Cells
Provided is a method of quantifying an antigen-binding molecule bound to cells, comprising: a preparation step of preparing a biological sample derived from the cells, wherein the biological sample is homogenized, the cells express a target antigen bound specifically to the antigen-binding molecule, and the cells have been exposed to the antigen-binding molecule; an extraction step of adding an extraction solution to the biological sample to obtain an analyte, wherein the extraction solution comprises an organic acid and a nonionic surfactant, and the extraction solution has a pH of 1 or more and 3 or less; and a quantification step of analyzing the analyte to quantify the antigen-binding molecule.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
21.
METHOD FOR PRODUCING PROLIFERATIVE MACROPHAGE-LIKE CELLS (pMAC)
The present invention provides a proliferating macrophage-like cell (pMAC) characterized by proliferation in a cytokine-dependent manner, a production method thereof, and a method for producing CAR-pMAC, including (1) a step of, in a pluripotent stem cell, deleting the gene that inhibits a macrophage-like function or suppressing expression of the gene, and then inducing differentiation into a myeloid cell to obtain a macrophage-like cell (MAC) (step 1), (2) a step of expressing the gene that confers proliferating property in the MAC obtained in step 1 to obtain a proliferating macrophage-like cell (pMAC) (step 2), and (3) a step of introducing a chimeric antigen receptor (CAR) (step 3). Furthermore, the present invention provides a pharmaceutical use of CAR-pMAC. According to the present invention, it is possible to provide a novel CAR-loaded cell platform, particularly, a novel CAR-loaded cell platform superior in stable quality, stable supply, and economic efficiency, particularly, a novel CAR-loaded cell platform superior as a medicament.
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
The present invention provides a T cell receptor or a fragment thereof which is capable of binding to a peptide having the amino acid sequence represented by SEQ ID NO: 20 or a complex of the peptide and HLA-A02, wherein the peptide includes the amino acid sequences for CDR1 to CDR3 which are respectively represented by SEQ ID No. 1 to SEQ ID No. 3 as complementarity determining regions in an α-chain and the amino acid sequences for CDR1 to CDR3 which are respectively represented by SEQ ID No. 7 to SEQ ID No. 9 as complementarity determining regions in a β-chain, or includes the amino acid sequences for CDR1 to CDR3 which are respectively represented by SEQ ID No. 4 to SEQ ID No. 6 as complementarity determining regions in the α-chain and the amino acid sequences for CDR1 to CDR3 which are respectively represented by SEQ ID No. 10 to SEQ ID No. 12 as complementarity determining regions in the β-chain.
C12N 15/12 - Gènes codant pour des protéines animales
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
Gripping forceps according to the present invention include a sheath which extends in a longitudinal direction; and a gripping portion which has a rod provided at a distal end of the sheath and extending in the longitudinal direction, a first jaw coupled to a proximal end side of the rod and being opened and closed toward a distal end side of the rod, and a second jaw coupled to the proximal end side of the rod on a side opposite to the first jaw with the rod sandwiched therebetween and being opened and closed toward the distal end side of the rod. The rod has a distal end portion which includes a first convex portion protruding to a first protrusion side toward the first jaw.
An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Provided is a novel antibody-light absorber conjugate for PIT. Provided is an antibody-light absorber conjugate for repeated administration in optimal photoimmunotherapy (PIT) for humans.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
26.
ANTIBODY AGAINST INTERLEUKIN-7 RECEPTOR (IL-7R), AND ANTIBODY-DRUG CONJUGATE (ADC) INCLUDING SAID ANTIBODY
The present disclosure relates to: an isolated monoclonal antibody capable of binding to a human interleukin-7 receptor (IL-7R), or an antigen-binding fragment thereof; a humanized antibody or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or an antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
28.
PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD
Provided is a kit or a device for the detection of pancreatic cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, including measuring the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
[Problem] To provide a processing device, a processing program, a processing method, and a processing system with which it is possible to more efficiently make an assessment relating to the onset of delirium. [Solution] A processing device comprising at least one processor, wherein the at least one processor is configured so as to execute processing for: acquiring, via a communication interface, subject information indicating the state of a subject receiving medical treatment from a medical institution; acquiring the result of assessing the onset of delirium by inputting the acquired subject information into a trained assessment model used for performing assessment relating to the onset of delirium; and outputting the acquired assessment result via the communication interface.
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
30.
COMPUTER PROGRAM, LEARNED MODEL GENERATION METHOD, IMAGE PROCESSING METHOD, AND IMAGE PROCESSING DEVICE
The present invention provides a computer program, a learned model generation method, an image processing method, and an image processing device for easily acquiring the risk of nerve damage. A computer executes processing for supporting endoscopic surgery according to a computer program according to the present invention. The computer program causes the computer to execute processing of acquiring an endoscopic image of the inside of the body, photographed by an endoscope, and outputting, on the basis of the acquired endoscopic image, information indicating a risk of damaging a nerve inside the body.
The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
32.
IMAGE PROCESSING DEVICE, SURGERY SUPPORT SYSTEM, IMAGE PROCESSING METHOD, AND PROGRAM
An image processing device according to the present invention comprises: an image acquisition unit that acquires a surgical field image obtained by imaging a surgical field in endoscopic surgery; a region recognition unit that inputs the surgical field image acquired by the image acquisition unit into a trained model, which has learned training data obtained by adding a region indicating a tissue classification to a training image obtained by imaging a surgical field, and thereby recognizes a region included in the surgical field image; a structure detection unit that detects a fibrous structure which is included in the surgical field image acquired by the image acquisition unit; and an image output unit that outputs a surgical field image indicating the fibrous structure which is included in the region recognized by the region recognition unit.
An endoscope system includes: an endoscope including an elongated portion in which an imaging optical system is arranged; an arm supporting the endoscope; and a unit capable of changing a field-of-view direction of the endoscope, wherein each library data stored in a storage includes a parameter related to relative position and attitude between the imaging optical system and an observation object, the parameter includes a first parameter or a second parameter, the first parameter determined by a sum of an inclination of a longitudinal axis of the elongated portion and an amount of curvature of the changing unit on base coordinates, the first parameter related to an orientation of the imaging optical system on the base coordinates, the second parameter indicating an orientation of the imaging optical system as viewed from a coordinate of the observation object, and the unit or the arm based on the library data is controlled.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
The problem to be solved by the present invention is to further improve a therapeutic effect by performing dose evaluation at the time of theranostics with higher accuracy. Provided is a dose evaluation method comprising: a step (S104) for generating pharmacokinetic data of a therapeutic agent administered to a patient during radiation treatment; a step (S108) for acquiring radiation dose distribution data indicating the dose distribution of radiation emitted to the body of the patient during radiation treatment; and a step (S110) for generating, on the basis of the radiation dose distribution data and the pharmacokinetic data, in-vivo dose distribution data obtained by adding together the radiation emitted to the body of the patient during radiation treatment and radiation generated in the body of the patient by irradiation with radiation.
This application provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
Provided is a method for collecting data for predicting symptoms of a breakthrough infection in a subject who received a SARSr-CoV vaccine, the method comprising: a step for preparing a leukocyte-containing specimen collected from the subject; a step for adding a plurality of peptides to the specimen; and a step for measuring the level of expression of mRNA of any one of T cell function-related markers selected from the group consisting of IFNγ, CXCL9, CXCL10, and IL-1A. The plurality of peptides correspond to a plurality of fragments of the amino acid sequence of a spike protein, and cover 40% or more of the total length of the amino acid sequence of the spike protein. If the level of expression of the mRNA of the T-cell function-related marker is equal to or higher than a predicted reference level, the subject is predicted to be asymptomatic in a case where a breakthrough infection occurs in the subject. If the expression level of the mRNA of the T-cell function-related marker is less than the predicted reference level, the subject is predicted to be symptomatic in case where a breakthrough infection occurs in the subject.
Provided is a method or apparatus for predicting treatment response to an immune checkpoint inhibitor, the method comprising: determining a density of tumor-infiltrating lymphocytes (TILs) for a pathological image at a first time point using a machine learning model; determining a density of TILs for a pathological image at a second time point using the machine learning model; determining a fold change in density of TILs by using the density of TILs for the pathological image at the first time point and the density of TILs for the pathological image at the second time point; and predicting a treatment response to the immune checkpoint inhibitor in a cancer patient based on the fold change in density of the TILs. According to a method of one aspect, the treatment responsiveness to an immune checkpoint inhibitor in cancer patients can be more accurately predicted and a treatment method can be determined.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present disclosure relates to a method and device for predicting a treatment response to a HER2-targeted therapeutic agent. In an embodiment, a method of more accurately predicting the therapeutic responsiveness of a cancer patient to the HER2-targeted therapeutic agent and treating cancer may be determined.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
An information processing apparatus (2000) detects an abnormal region (30) in each of a plurality of video frames (14) constituting video data (12) in which the inside of a body is captured. The information processing apparatus (2000) outputs output information related to the detected abnormal region (30). Herein, the information processing apparatus (2000) starts outputting of the output information when a detection score based on a proportion of the number of the video frames (14) in which the abnormal region (30) is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus (2000) ends outputting of the output information 10 when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
An information processing apparatus (2000) detects an abnormal region (30) in each of a plurality of video frames (14) constituting video data (12) in which the inside of a body is captured. The information processing apparatus (2000) outputs output information related to the detected abnormal region (30). Herein, the information processing apparatus (2000) starts outputting of the output information when a detection score based on a proportion of the number of the video frames (14) in which the abnormal region (30) is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus (2000) ends outputting of the output information when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
An information processing apparatus (2000) detects an abnormal region (30) in each of a plurality of video frames (14) constituting video data (12) in which the inside of a body is captured. The information processing apparatus (2000) outputs output information related to the detected abnormal region (30). Herein, the information processing apparatus (2000) starts outputting of the output information when a detection score based on a proportion of the number of the video frames (14) in which the abnormal region (30) is detected becomes equal to or more than a first threshold value in a state where outputting of the output information is not being performed. Further, the information processing apparatus (2000) ends outputting of the output information when the detection score becomes equal to or less than a second threshold value in a state where outputting of the output information is being performed.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting early pancreatic cancer or a pancreatic cancer precursor lesion, comprising measuring an expression level(s) of the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
43.
ENDOSCOPE SYSTEM, METHOD FOR CONTROLLING ENDOSCOPE SYSTEM, AND RECORDING MEDIUM
An endoscope system includes an endoscope to be inserted into a subject to acquire an image, a robot arm that is configured to change the position and the posture of the endoscope, and a controller including a processor. The controller is configured to: acquire treatment instrument information concerning the position or the movement of a treatment instrument to be inserted into the subject, determine whether the treatment instrument has been removed based on the treatment instrument information, in response to determining that the treatment instrument has been removed, execute an overlooking mode, and in the overlooking mode, control at least one of the endoscope or the robot arm to thereby automatically zoom out the image while maintaining, in the image, a specific point in the subject.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
Disclosed herein are methods for predicting the clinical or disease outcome of a subject with a disease. The methods for generating an index to predict the disease outcome are also provided. The methods comprise procedures for measuring miRNA levels in a cell-free sample of a subject. The compositions for practicing the same are further provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
This application provides a kit or a device for detection of lung cancer, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
46.
BIOPSY FORCEPS, ENDOSCOPIC PROCEDURE SYSTEM, AND METHOD FOR COLLECTING TISSUE USING ENDOSCOPIC PROCEDURE SYSTEM
The present invention is biopsy forceps that can be inserted into a puncture hole formed by using a needle to puncture a biological tissue, said biopsy forceps comprising: a first forceps piece that is long in one direction and has a forceps cup in which a recess capable of collecting the biological tissue is formed; and a second forceps piece that is positioned on the recess opening side of the first forceps piece. The first forceps piece can open and close, toward the distal end side in the lengthwise direction, with regard to the second forceps piece. The forceps cup has, in the lengthwise direction, a body section and a distal end section that is provided on the distal end side of the body section. In the distal end section, the length in a direction that is perpendicular to the lengthwise direction gradually decreases toward the distal end side.
A learning support device includes a processor. The processor is configured to: form a foreground image containing at least one treatment instrument by placing an image of the at least one treatment instrument within an image region; form a superimposed image by superimposing the foreground image on a background image; and form a training image by adjusting at least one of hue, saturation, or brightness of the superimposed image.
G06T 5/50 - Amélioration ou restauration d'image utilisant plusieurs images, p. ex. moyenne ou soustraction
G06T 5/92 - Modification de la plage dynamique d'images ou de parties d'images basée sur les propriétés globales des images
G06T 7/194 - DécoupageDétection de bords impliquant une segmentation premier plan-arrière-plan
G06V 10/60 - Extraction de caractéristiques d’images ou de vidéos relative aux propriétés luminescentes, p. ex. utilisant un modèle de réflectance ou d’éclairage
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
48.
ESOPHAGEAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD
It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample of a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
49.
ENDOSCOPE SYSTEM, METHOD FOR CONTROLLING ENDOSCOPE SYSTEM, AND RECORDING MEDIUM
An endoscope system includes: an endoscope configured to acquire an image; and at least one processor including hardware. The at least one processor is configured to: acquire a distance from a treatment tool to target, acquire an operation state of the treatment tool, and determine a necessity for zooming in and zooming out on the basis of at least one of the distance and the operation state.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
50.
METHOD AND DEVICE FOR PRODUCING COMPOSITION FOR TISSUE REGENERATION
A method for producing a composition for tissue regeneration according to the present invention comprises: a step for extracting adipose tissue-derived stem cells from a first adipose tissue collected from a human body; a step for culturing the adipose tissue-derived stem cells; and a step for mixing the cultured adipose tissue-derived stem cells with a second adipose tissue newly collected from the human body. The weight of each of the first adipose tissue and the second adipose tissue may be 5-30 g inclusive. Thus, the present invention can provide a composition for tissue regeneration which enables less invasive regenerative medicine.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
51.
Biliary tract cancer detection kit or device, and detection method
The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
52.
THREE-DIMENSIONAL TUMOR TISSUE MODEL, AND PRODUCTION METHOD THEREOF
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
NATIONAL CANCER CENTER (Japon)
Inventeur(s)
Mori Nobuhito
Kida Yasuyuki
Koga Yoshikatsu
Tsumura Ryo
Abrégé
One purpose of the present disclosure is to provide a three-dimensional tumor tissue model having a main vessel-like structure and a tumor vessel-like structure, and a production method of the same. Another purpose of the present disclosure is to provide a method for evaluating the effect of an evaluation target on a tumor tissue using the three-dimensional tumor tissue model. The three-dimensional tumor tissue model of the present disclosure has a main vessel-like structure and a tumor vessel-like structure connected to the main vessel-like structure, and contains vascular cells, cancer cells, and extracellular matrix.
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
The present invention relates to an antibody drug conjugate in which an antibody that binds to tissue factor and Dxd that is the cytotoxic agent are bound via a linker composed of maleimide caproyl-glycine-glycine-phenylalanine-glycine.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
54.
COLORECTAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD
It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
55.
PHARMACEUTICAL COMPOSITION FOR TREATING HPV TESTED-POSITIVE CANCER OR HPV PRETESTED-POSITIVE CANCER PATHOLOGICAL CHANGE GENE, AND RECOMBINANT ADENOVIRUS VECTOR
This pharmaceutical composition is for treating human papilloma virus (HPV) tested-positive cancer or an HPV pretested-positive cancer pathological change gene, and includes: Cas guide RNA or a nucleic acid molecule encoding the same; and a Cas9 nickase or a nucleic acid molecule encoding the same. The Cas guide RNA or the nucleic acid molecule encoding the same includes a pair of specific Cas guide RNA or a pair of nucleic acid molecules encoding the same, or a combination of such pairs.
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
TREATMENT INSTRUMENT DETECTION DEVICE FOR ENDOSCOPIC IMAGES, TREATMENT INSTRUMENT DETECTION METHOD FOR ENDOSCOPIC IMAGES, AND TREATMENT INSTRUMENT DETECTION DEVICE PROGRAM FOR ENDOSCOPIC IMAGES
The purpose of the present invention is to provide a treatment instrument detection device for endoscopic images which increases the accuracy with which the position of a treatment instrument in an endoscopic image can be ascertained. This treatment instrument detection device for endoscopic images comprises: an image acquisition unit which acquires a surgical image; an image recognition unit which uses a pre-trained deep learning model to perform image recognition on the surgical image; a treatment instrument extraction unit which generates a treatment instrument region comprising a segmentation mask and a bounding box within a treatment instrument image in the surgical image; and a treatment instrument region inpainting unit which inpaints an omission in the treatment instrument region due to an obstacle present in the surgical image. The treatment instrument region inpainting unit comprises an image inpainting unit which generates a colour processing image and inpaints the treatment instrument image. The treatment instrument region inpainting unit may comprise a rectangle inpainting unit which, for the segmentation mask of the treatment instrument output by the treatment instrument extraction unit, generates the smallest rectangle surrounding the treatment instrument region acquired by image processing and uses the smallest rectangle to perform inpainting.
The present invention provides a fusion protein suitable for dissolving a fibrin clot and a pharmaceutical composition containing the fusion protein. According to the present invention, there is provided a fusion protein of an antibody that binds to insoluble fibrin or an antigen-binding fragment thereof and a prourokinase mutant, in which amino acid sequence of a plasmin in a kringle domain is modified so as to be less cleavable with a plasmin, and a pharmaceutical composition containing the fusion protein.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.
An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
H04N 5/272 - Moyens pour insérer une image de premier plan dans une image d'arrière plan, c.-à-d. incrustation, effet inverse
61.
IMAGE PROCESSING DEVICE, SURGICAL SUPPORT SYSTEM, IMAGE PROCESSING METHOD, AND PROGRAM
This image processing device is provided with: an image acquisition unit that acquires an operating field image that is an image of an operating field for a scope-assisted surgery; a region recognition unit that recognizes an excising region showing an area of a tissue to be excised and a preserving region showing an area of a tissue to be preserved both included in the operating field image by inputting the operating field image acquired by the image acquisition unit into a trained model trained using learning data in which the excising region and the preserving region are applied to a learning image that is an image of the operating field; and an image output unit that outputs, on the basis of a result of the recognition by the region recognition unit, an operating field image that shows a detachment recommendation region showing an area of a tissue to be detached.
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
62.
Lung cancer detection kit or device, and detection method
It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
A method for predicting the success in a test subject of a cancer treatment drug which regulates splicing function, said method involving a step for determining the presence/absence of a mutation in a homologous recombination repair-related gene by using a specimen collected from the test subject, and a step for predicting the success in the test subject of the cancer treatment drug for regulating splicing function on the basis of the presence/absence of said mutation.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
64.
Anti-TSPAN8/anti-CD3 bispecific antibody and anti-TSPAN8 antibody
An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention provides a convenient and noninvasive detection method for assisting in the determination of pancreatic cystic tumor to be benign or malignant, and a kit for detection therefor. Specifically, the present invention provides a method for assisting in the determination of malignant pancreatic cystic tumor, the method comprising the steps of measuring in vitro the amount of APOA2-AT protein or/and APOA2-ATQ protein present in a body fluid sample of a test subject having pancreatic cystic tumor, and assisting in determining the pancreatic cystic tumor to be benign or malignant on the basis of the amount, and a kit for assisting in the determination of malignant pancreatic cystic tumor, the kit being directed to measuring the amount of APOA2-AT protein or/and APOA2-ATQ protein and being usable in the method.
In this information processing method, an information processing device: acquires brain wave signals successively from a brain wave measurement device attached to the ear of a user; uses the successively acquired brain wave signals and a learning model that has learned learning data including brain wave signals and sedation depths corresponding to the brain wave signals, to estimate sedation depths corresponding to the successively acquired brain wave signals; and outputs sedation depth information regarding the estimated sedation depth.
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
67.
NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION
A compound represented by formula (1) below, useful for treating cancer. In the formula, R1 and R3-R8 each independently represents a hydrogen atom or an alkyl group, R2 represents a hydrogen atom or a group represented by —ORa, R9 represents a group represented by —C(O)NRcRf, Ra, Re, and Rf each independently represents a hydrogen atom, an arylalkyl group that may have a substituent, or a heteroarylalkyl group. A production method that enables the compound to be produced with high efficiency, and a pharmaceutical composition containing the compound as an active ingredient
A compound represented by formula (1) below, useful for treating cancer. In the formula, R1 and R3-R8 each independently represents a hydrogen atom or an alkyl group, R2 represents a hydrogen atom or a group represented by —ORa, R9 represents a group represented by —C(O)NRcRf, Ra, Re, and Rf each independently represents a hydrogen atom, an arylalkyl group that may have a substituent, or a heteroarylalkyl group. A production method that enables the compound to be produced with high efficiency, and a pharmaceutical composition containing the compound as an active ingredient
C07D 263/32 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 277/30 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
68.
Kit, device and method for detecting prostate cancer
This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
NATIONIAL CANCER CENTER (Japon)
Inventeur(s)
June, Carl H.
Watanabe, Keisuke
Young, Regina M.
Scholler, John
Nishikawa, Hiroyoshi
Abrégé
The present disclosure provides anti-CCR4 chimeric antigen receptors (CARs) and compositions and methods for modified immune cells or precursors thereof (e.g., modified T cells) comprising anti-CCR4 CARs. Also provided are methods of using the anti-CCR4 CAR-expressing cells to treat cancer and T cell-depleting systems for use in combination with anti-CCR4 CAR T cell therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
70.
IMAGE SEARCH DEVICE, IMAGE SEARCH METHOD, AND IMAGE SEARCH PROGRAM
A processor receives an input of finding information indicating at least one finding, which is desired to be searched for, on a query base image, which includes a part desired to be searched for and is a source of a query image, to derive the query image to which the finding has been added, derives at least one added finding feature amount indicating an image feature for the added finding, and derives a query normal feature amount indicating an image feature for a normal region included in the part in the query base image. The processor derives similarities between the query image and a plurality of reference images including findings on the basis of comparisons between the added finding feature amount and the query normal feature amount and the like with reference to an image database in which the plurality of reference images have been registered and extracts the reference image that is similar to the query image as a similar image from the image database on the basis of the similarities.
G06F 16/583 - Recherche caractérisée par l’utilisation de métadonnées, p. ex. de métadonnées ne provenant pas du contenu ou de métadonnées générées manuellement utilisant des métadonnées provenant automatiquement du contenu
G06F 16/532 - Formulation de requêtes, p. ex. de requêtes graphiques
71.
Stomach cancer detection kit or device, and detection method
Disclosed is a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, including measuring the miRNA(s) in vitro.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
72.
Breast cancer detection kit or device, and detection method
It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A full-thickness resection method for a gastrointestinal tract includes forming a pair of first markings in surrounding tissue on both sides of a lesion to sandwich the lesion therebetween; performing a full-thickness resection to a portion including the lesion; identifying a pair of suture locations in the vicinity of the pair of first markings; and suturing the pair of first suture locations.
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
This grasping forceps according to the present invention is provided with: a sheath extending in the longitudinal direction; a rod provided at the tip of the sheath and extending in the longitudinal direction; and a grasping part that has a first jaw connected to the base side of the rod and opening and closing toward the tip side of the rod, and a second jaw connected to the base side of the rod on the opposite side of the rod from the first jaw and opening and closing toward the tip side of the rod. The rod has a tip part provided with a first convex portion that protrudes toward the first jaw on a first protruding side.
To provide excellent operability and to enable proper return of body fluid retained in an abdominal cavity into a luminal organ, a body fluid reflux device 100 is configured to return the body fluid retained in the abdominal cavity into the luminal organ, and comprises a body part 110 and a check valve part 150. The body part 110 is formed in a cylindrical shape having a lumen and has a distal end 110d disposed in the luminal organ and a proximal end 110p disposed in the abdominal cavity. The check valve part 150 is provided on the proximal end 110p side of the body part 110, has an outlet that allows the fluid to flow out of the lumen of the body part 110 to the outside of the body part 110, and is configured to regulate the inflow of the fluid from the outside of the body part 110 to the lumen of the body part 110. At least the distal end 110d side of the body part 110 is constituted of a flexible tube member 120 made of a resin material.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
76.
Kit, device, and method for detecting bladder cancer
An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
77.
TERTIARY AMIDE DERIVATIVE SUBSTITUTED BY QUATERNARY CARBON
The present disclosure provides: a tertiary amide derivative substituted by quaternary carbon that is useful as a medicine and a pharmaceutically acceptable salt of the tertiary amide derivative; a pharmaceutical composition comprising these components; and a therapeutic or prophylactic agent for a disease condition in which CBP/P300 is involved, the therapeutic or prophylactic agent comprising the composition. More specifically, the present disclosure provides a compound represented by formula (1) [wherein A represents CR6aR6b222; B represents formula (B-1); the ring Q represents an optionally substituted 6- to 10-membered aromatic hydrocarbon ring or an optionally substituted 5- to 10-membered aromatic heterocyclic ring; Z represents -O-, -N(R7a)-, an optionally substituted 6- to 10-membered bivalent aromatic ring group, an optionally substituted 5- to 10-membered bivalent aromatic heterocyclic ring group, an optionally substituted 4- to 10-membered bivalent non-arylheterocyclic ring group; and R1, R2aand R2b, R3, R4, and R5 are as described in the description] or a pharmaceutically acceptable salt thereof.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
79.
METHOD FOR PRODUCING PROLIFERATIVE MACROPHAGE-LIKE CELLS (pMAC)
The present invention provides: proliferative macrophage-like cells (pMAC), characterized by proliferating in a cytokine-dependent manner; a method for producing the same; and a method for producing chimeric antigen receptor (CAR)-proliferative macrophage-like cells (pMAC) that includes (1) a step (step 1) that deletes or suppresses the expression of a gene that inhibits macrophage-like function in pluripotent stem cells, then induces differentiation into myeloid cells to obtain macrophage-like cells (MAC), (2) a step (step 2) that brings about expression of a gene that adds a proliferative property to the MAC obtained in step 1 and obtains proliferative macrophage-like cells (pMAC), and (3) a step (step 3) that introduces a CAR. The present invention also provides the pharmaceutical use of CAR-pMAC. The present invention makes it possible to provide a novel CAR-loaded cell platform, especially a CAR-loaded cell platform having excellent quality stability, stable supply, and economy, and especially to provide a CAR-loaded cell platform that is excellent as a pharmaceutical.
Provided is a method of assisting breast cancer diagnosis, comprising: a measuring step for measuring an amount of laminin 5 or laminin β3 in a specimen; and an information-providing step for providing information for breast cancer diagnosis based on the amount of laminin 5 or laminin β3 thus measured. Provided is a test kit for breast cancer comprising an anti-laminin 5 antibody or an anti-laminin β3 antibody.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
81.
GENETICALLY MODIFIED CELL AND METHOD FOR PRODUCING SAME
A genetically modified cell includes (i) an exogenous oligomeric polypeptide having a variable region and a constant region, and (ii) exogenous CD8 α-chain and β-chain polypeptides.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japon)
TOKYO UNIVERSITY OF SCIENCE FOUNDATION (Japon)
NATIONAL CANCER CENTER (Japon)
NIPPON MEDICAL SCHOOL FOUNDATION (Japon)
Inventeur(s)
Terao, Yasuhisa
Yoshida, Emiko
Kato, Hisamori
Ohtsu, Takashi
Ueno, Yuta
Kawaji, Hideya
Sozu, Takashi
Kato, Tomoyasu
Abrégé
The purpose of the present invention is to provide a method for evaluating the occurrence of lymph node metastasis of endometrial cancer or the lymph node metastasis capability of endometrial cancer with high accuracy. Provided is a method for evaluating the occurrence of lymph node metastasis of endometrial cancer, or the lymph node metastasis capability of endometrial cancer or the prognosis of endometrial cancer, the method comprising measuring a value of a specific parameter, then introducing the value to a model that is constructed by machine learning, and then evaluating the occurrence of lymph node metastasis of endometrial cancer, or the lymph node metastasis capability of endometrial cancer or the prognosis of endometrial cancer, in which the model is constructed by machine learning employing a value of the parameter in each patient in a teacher sample group including endometrial cancer patients with lymph node metastasis and endometrial cancer patients without lymph node metastasis as an explanatory variable and also employing data about the presence or absence of lymph node metastasis in each patient in the group as an objective variable.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
83.
INFORMATION MANAGEMENT APPARATUS AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM
An information management apparatus includes at least one processor configured to acquire first time information and second time information, the first time information being related to a time taken to acquire a predetermined amount of at least one or more specific nucleic acids based on a first cell acquired from a cancer patient, the second time information being related to a time taken to culture a second cell different from the first cell until a predetermined amount is reached; and store individual patient information in which the first time information and the second time information are associated with attribute information of the cancer patient.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
85.
Pancreatic cancer detection kit or device, and detection method
This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 37/00 - Détails non couverts par les autres groupes de la présente sous-classe
86.
PROGRAM, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING DEVICE
Provided are: a program which makes it possible to highly accurately detect the occurrence of bleeding from an image captured during a surgery; and others. A computer acquires a plurality of captured images each having a plurality of color components, which are images of a treated area taken on a time-series basis. The computer also acquires bleeding area images with respect to the acquired plurality of images, in which each of the bleeding area images shows a bleeding area in each of the captured images on the basis of the difference in the color components. The computer calculates a difference of bleeding area between bleeding area images of each of captured images before and after in time series, and determines the presence or absence of bleeding from the treated area on the basis of the difference of bleeding area.
A display processing unit causes a display device to display an endoscopic image of a living tissue in a somatic cavity captured by an endoscope. An operation reception unit receives a user operation that is performed so as to set an area of interest in the endoscopic image. An area-of-interest setting unit sets the area of interest in the endoscopic image based on the user operation. A three-dimensional information acquisition unit acquires three-dimensional shape information of the living tissue captured by the endoscope. A virtual surface derivation unit derives three-dimensional shape information of a virtual surface in the area of interest from three-dimensional shape information of an area different from the area of interest. A size information identification unit identifies information concerning a size of the virtual surface from the three-dimensional shape information of the virtual surface.
G06T 7/50 - Récupération de la profondeur ou de la forme
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
This double-balloon endoscope comprises: an elongated part that has an elongated shape and has, at the distal end thereof, a balloon that expands and contracts, the distal end portion of the elongated part being capable of being bent by an operation from the exterior; and a cylindrical part that has a cylindrical shape and has, at the distal end thereof, another balloon that expands and contracts, the distance end portion of the cylindrical part being capable of being bent by an operation from the exterior.
[Problem] To provide a novel T-cell receptor (TCR) which specifically recognizes glypican 3 (GPC3). [Solution] Provided is a T-cell receptor (TCR) that includes one amino acid sequence selected from the group consisting of the amino acid sequences represented by sequence numbers 1-13 as a complementarity determining region of an α chain, and that includes one amino acid sequence selected from the group consisting of the amino acid sequences represented by sequence numbers 14-28 as a complementarity determining region of a β chain.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A method for determining effectiveness of a cancer treatment using a RET kinase inhibitor, the method comprising: a step for detecting, in a sample isolated from a subject, an amino acid mutation in a calmodulin-like motif of a RET protein; and a step for, if the amino acid mutation is detected in said step, determining that the cancer treatment using the RET kinase inhibitor is highly effective for the subject.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
91.
PRODUCTION METHOD FOR PROLIFERATIVE MYELOID CELLS THAT CONSTITUTIVELY PRODUCE IL-12P70
Provided is a production method for proliferative myeloid cells that constitutively produce IL-12p70, the method comprising: (1) a step for introducing a nucleic acid encoding c-MYC into myeloid cells; (2) a step for culturing the cells obtained in step (1) in the presence of GM-CSF and M-CSF; and (3) a step for introducing a nucleic acid encoding an IL-12p35 subunit and a nucleic acid encoding an IL-12p40 subunit into the cells obtained in step (2).
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
CANCER VACCINE USING COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING CANCER ONSET RISK BY BLOOD-CIRCULATING CANCER CELL DETECTION
The present invention addresses the problem of providing a cancer vaccine that uses a common cancer antigen cocktail, a TCR/CAR-T cell therapeutic, a companion diagnostic method, and a method for diagnosing cancer onset risk by blood-circulating cancer cell detection. The present invention provides a cancer vaccine that includes (1) common cancer antigens including 3 or more of GPC3, ROBO1, EPHB4, CLDN1, and LAT1, (2) partial peptides of the 3 or more common cancer antigens that have CTL inducibility, (3) dendritic cells stimulated by the partial peptides, or (4) mRNA that codes for the common cancer antigens or the partial peptides.
To provide a pharmaceutical composition capable of enhancing the effect of an immune checkpoint inhibitor against tumor or cancer in a subject. Provided is a pharmaceutical composition that comprises bacterial cells, a culture supernatant, a metabolite, and/or a bacterial cell extract of Ruminococcaceae enterobacterium, and is administered in combination with an immune checkpoint inhibitor.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
95.
Information processing device, display method, and non-transitory computer-readable medium for storing a program for lesion detection processing supporting decision making using machine learning
Provided are an information processing device, a display method, and a program that allow to easily grasp during examination that a lesion is captured how long before from now which is detected by detection processing for an image captured by an endoscope. An information processing device includes: an image acquisition unit configured to sequentially acquire a current image captured by an endoscope; a lesion detection unit configured to sequentially perform detection processing of a lesion site on the images sequentially acquired by the image acquisition unit; and a display control unit configured to display, on a display device, a degree of lapse of time up to a current time from a capturing time of the image in which the lesion site is detected by the lesion detection unit.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A medical stapler includes an attachment-detachment portion that is attachable to and detachable from a distal-end portion of an endoscope; a grasping portion arranged at a distal-end side of the attachment-detachment portion and configured to grasp target tissue and suture the grasped target tissue; and an advancement-retraction mechanism configured to connect the grasping portion to the attachment-detachment portion such that the grasping portion is advanceable and retractable with respect to the attachment-detachment portion, wherein the advancement-retraction mechanism includes a wire sheath inserting through a penetration hole formed in the attachment-detachment portion, a distal end of the wire sheath is fixed to the grasping portion, and the grasping portion moves to the distal-end side by moving the wire sheath toward the distal-end side.
A medical stapler includes an attachment-detachment portion attached to a distal-end portion of an endoscope and including an opening from which an objective lens of the endoscope is exposed; and a grasping portion attached to the attachment-detachment portion and including a first grasping portion and a second grasping portion connected by a rotation shaft to be openable and closeable, wherein the second grasping portion includes a visual-field space penetrating a gap between the staple reception portion and the rotation shaft in an open-close direction, when the grasping portion is in the closed state, the staple extraction portion and the staple reception portion are opposite to each other, and when the grasping portion is in an open state, an optical axis of the objective lens passes through the visual-field space.
This endoscope system comprises: an electric scope 3 equipped with a camera for capturing an observation target; a robot arm 5 that changes the position and posture of the electric scope 3 while supporting the electric scope 3; a curved portion with which the viewing direction of the electric scope 3 can be changed; an auxiliary storage device 27 that stores a plurality of sets of library data for reproducing endoscopic views associated with respective procedure scenes; and at least one curvature controller 23 and position/posture controller 25. The library data includes at least one relative parameter relating to the relative position and posture between the camera and the observation target, and after calling library data associated with a certain procedure scene from the auxiliary storage device 27, the curvature controller 23 and the position/posture controller 25 control at least one of the curved portion and the robot arm 5 on the basis of the called library data.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
99.
BIOMARKER FOR TREATMENT OF SOLID CANCER BY IMIDAZO[4,5-B]PYRIDINE DERIVATIVE
Provided is a means for predicting the anti-cancer therapeutic efficacy of 1-((5-(1R)-1-fluoroethyl)-1,3,4-oxadiazol-yl)methyl)-6-(4-methoxypyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-1H-imidazo[4,5-b]pyridine or a derivative thereof in solid cancer, and for identifying a subject that is most likely to benefit from treatment using said compound and treatment using the compound in combination with other agents and/or other therapies. As a biomarker for predicting a treatment response to the compound, the feature of a gene expected to impart sensitivity to CLK inhibition is used.
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
Disclosed herein are methods for predicting the clinical or disease outcome of a subject with a disease. The methods for generating an index to predict the disease outcome are also provided. The methods comprise procedures for measuring miRNA levels in a cell-free sample of a subject. The compositions for practicing the same are further provided.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
